Matching
Match the treatment with its target.
Premises:
ipilimumab
brentuximab
ibritumomab
lirilumab
nivolumab
elotuzumab
vemurafenib
Responses:
CD30
CD20
BRAF
programmed death 1 (PD-1)
CTLA-4
CD319
HLA-C-specific inhibitory KIRs
Correct Answer:
Premises:
Responses:
ipilimumab
brentuximab
ibritumomab
lirilumab
nivolumab
elotuzumab
vemurafenib
Premises:
ipilimumab
brentuximab
ibritumomab
lirilumab
nivolumab
elotuzumab
vemurafenib
Responses:
Related Questions
Q10: _ describes the condition in which a
Q11: A.How is it possible for a tumor-specific
Q12: Adoptive transfer of sipuleucel-T-primed dendritic cells is
Q13: Human papillomaviruses express proteins that bind to
Q14: A tumor-associated antigen normally expressed only in
Q16: An example of a physical agent that
Q17: A.What is Li-Fraumeni syndrome?<br>B.What is the underlying
Q18: Provide an example of a monoclonal antibody
Q19: A protein expressed in response to damage
Q20: Li-Fraumeni syndrome is linked to a greater